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ANP: atrial natriuretic peptide 
β-MHC: beta-myosin heavy chain  
BNP: brain natriuretic peptide 
CardiomiRs: cardiac enriched miRNAs 
Ct: cycle threshold 
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EF: ejection fraction 
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GSK3: glycogen synthase kinase 3 
HCM: hypertrophic cardiomyopathy 
IGF-1: insulin-like growth factor 1 
i.p.: intra peritoneal 
IVRT: isovolumetric relaxation time  
LV: left ventricle 
LVID: left ventricle internal diameter  
miRNA: microRNA 
mTOR: mammalian target of rapamycin 
MV: mitral valve 
PA: propionic acidemia 
PCC: propionyl-CoA carboxylase 
PI3K/AKT: phosphatidylinositol 3 kinase-protein kinase B  
ROS: reactive oxygen species 






Cardiac alterations (hypertrophic/dilated cardiomyopathy, HCM/DCM, and 
rhythm alterations) are one of the major causes of mortality and morbidity in propionic 
acidemia (PA), caused by the deficiency of the mitochondrial enzyme propionyl-CoA 
carboxylase (PCC), involved in the catabolism of branched-chain amino acids, 
cholesterol and odd-chain fatty acids. Impaired mitochondrial oxidative phosphorylation 
has been documented in heart biopsies of PA patients, as well as in the hypomorphic 
Pcca-/-(A138T) mouse model, in the latter correlating with increased oxidative damage 
and elevated expression of cardiac dysfunction biomarkers atrial and brain natriuretic 
peptides (ANP and BNP) and beta-myosin heavy chain (β-MHC). Here we characterize 
the cardiac phenotype in the PA mouse model by histological and echocardiography 
studies and identify a series of upregulated cardiac-enriched microRNAs (miRNAs) in 
the PA mouse heart, some of them also altered as circulating miRNAs in PA patients’ 
plasma samples. In PA mice hearts we show alterations in signaling pathways regulated 
by the identified miRNAs, which could be contributing to cardiac remodelling and 
dysfunction; notably, an activation of the mammalian target of rapamycin (mTOR) 
pathway and a decrease in autophagy, which are reverted by rapamycin treatment. In 
vitro studies in HL-1 cardiomyocytes indicate that propionate, the major toxic 
metabolite accumulating in the disease, triggers the increase in expression levels of 
miRNAs, BNP and β-MHC, concomitant with an increase in reactive oxygen species 
(ROS).  Our results highlight miRNAs and signaling alterations in the PCC-deficient 
heart which may contribute to the development of PA-associated cardiomyopathy and 
provide a basis to identify new targets for therapeutic intervention. 
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MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene 
expression through translational repression or transcript degradation via binding to 
complementary sequences in the 3’-UTR of target mRNAs. To date, evidence has 
accumulated identifying miRNA networks that govern most biological processes and 
signaling pathways in response to different stimuli [1]. Therefore, miRNA 
dysregulation negatively affects cellular physiology and contributes to disease 
development. Alterations in miRNA function have been reported in many human 
disorders including cancer, cardiovascular, neurodegenerative and metabolic diseases 
[2]. In addition to their role as critical contributors to cellular pathophysiology, the 
discovery of the stable presence of miRNAs in body fluids in relation to disease has laid 
the foundations for their clinical use as minimal invasive biomarkers for diagnosis, 
prognosis or treatment monitoring [3].  
 In inherited metabolic diseases different reports have described an altered 
miRNA profile in animal models and in patients’ samples [2]. Plasma miRNA levels as 
biomarkers for disease and treatment response have been described [4], as well as 
modulation of miRNA levels as therapeutic approach [5]. In propionic acidemia (PA, 
MIM#606054), one of the most frequent life-threatening organic acidemias, caused by a 
defect in the mitochondrial enzyme propionyl-CoA carboxylase (PCC, E.C.6.4.1.3), we 
recently identified a set of altered miRNAs in liver of the hypomorphic mouse model 
Pcca-/-(A138T) [6]. Three of them, miR-34a, miR-338 and miR-350 were found 
upregulated in brain and heart tissue and the first two were also detected in altered 
levels in PA patients’ plasma, underlying their possible contribution to disease 
pathophysiology and their potential as disease biomarkers [6].  
 PA results from mutations in either the PCCA or PCCB genes, encoding both 
subunits of the PCC enzyme, and is characterized by the toxic accumulation of 
propionyl-CoA and derived metabolites. This produces a secondary mitochondrial 
dysfunction, an energetic defect and cellular oxidative damage [7]. PA usually presents 
neonatally as a toxic encephalopathy although there are milder late-onset forms. 
Advances in supportive treatment based on protein restriction and carnitine 
supplementation have allowed patients to live beyond the neonatal period. However, the 
overall outcome remains poor in most patients, who suffer from numerous 
complications related to disease progression, among them cardiac alterations 
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(arrythmias, dilated or hypertrophic cardiomyopathy (DCM or HCM)), a major cause of 
PA morbidity and mortality [8, 9].  The hypomorphic PA mouse model mimics the 
biochemical and clinical signs of the disease. It exhibits elevated expression of Nppa, 
Nppb and Myh7, encoding atrial natriuretic peptide (ANP), brain natriuretic peptide 
(BNP) and β-myosin heavy chain (β-MHC), respectively, biomarkers of cardiac 
dysfunction [6, 10]. Recently, using this model we have demonstrated the potential role 
of impaired Ca2+ handling in arrythmias and cardiac dysfunction in PA [11]. 
Given these observations, in this study we have characterized the cardiac 
phenotype by histological and echocardiography studies in hypomorphic PA mice and 
analysed levels of cardiac enriched miRNAs (cardiomiRs), their target genes and 
regulated signaling pathways. Evidence of the clinical relevance of these findings was 
provided by the analysis of these cardiomiRs in PA patients’ plasma samples. The 
results provide new insights into miRNA-mediated altered cellular processes involved 
in the development of PA-associated cardiomyopathy.  
 
Material and Methods 
Mice handling. All mice used, wild-type (wt) and hypomorphic Pcca-/-(A138T), were 
adults (5-8 month-old) in an FVB background [10]. Both males and females were 
included in all experiments except in the echochardiographic analysis, in which only 
males were studied. Mice were maintained on standard chow. All the experiments were 
carried out in a pathogen-free environment at the Animal Facility of Centro de Biología 
Molecular Severo Ochoa, in accordance with the Spanish Law of Animal Protection. 
The Institutional Animal Experimentation Ethical Committee (Universidad Autónoma 
de Madrid, reference CEI 963-A026) and the Regional Environment Department 
(Comunidad de Madrid, reference PROEX 22/14) approved all animal experiments. 
Genomic DNA isolated from tail biopsies was used for animal genotyping, as 
previously described [10]. 
Mice echocardiography. Transthoracic echocardiography was blinded performed by an 
expert operator in the CNIC Imaging facility 
(https://www.cnic.es/en/investigacion/imaging) using a high-frequency ultrasound 
system (Vevo 2100, Visualsonics Inc., Canada) with a 40-MHz linear probe. Two-
dimensional (2D) and M-mode (MM) echography were performed at a frame rate above 
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230 frames/sec, and pulse wave Doppler (PW) was acquired with a pulse repetition 
frequency of 40 kHz. Mice were lightly anesthetized with 1-2% isoflurane in oxygen, 
adjusting the isoflurane delivery trying to maintain the heart rate in 450±50 bpm. Mice 
were placed in supine position using a heating platform and warmed ultrasound gel was 
used to maintain normothermia. A base apex electrocardiogram was continuously 
monitored. Images were transferred to a computer and were analyzed off-line using the 
Vevo 2100 Workstation software. 
For left ventricular (LV) systolic function assessment, parasternal standard 2D and MM, 
long and short axis views (LAX and SAX view, respectively) were acquired. LV 
ejection fraction, LV fractional shortening, and LV chamber dimensions were calculated 
from these views [12]. Mitral valve (MV) inflow pattern was acquired using PW 
Doppler echography in the 4-chamber apical view to assess diastolic function. The 
sample volume was positioned parallel to the blood flow, across the mitral orifice. Early 
and late diastolic velocity peak wave (E and A, respectively), the E/A ratio and 
isovolumetric relaxation time (IVRT) were measured [13]. 
Transmission Electron Microscopy (TEM).  Cardiac tissue was collected immediately 
after mice were euthanized by exsanguination and placed in Trump’s fixative (1% 
glutaraldehyde/4% formalin in 0.1M phosphate buffer), post-fixed in 1% osmium 
tetroxide, dehydrated in ethanol and embedded in Spurr epoxy resin. The tissue was 
sectioned at 800 angstroms, placed onto copper grids and stained with lead citrate.  
Sections were viewed using a model 1400 transmission electron microscope (JEOL, 
Tokyo, Japan) at an accelerating voltage of 80KeV.   
Rapamycin treatment. Rapamycin (LC laboratories, Boston, Massachusetts, USA) was 
dissolved in ethanol at 20 mg/mL and diluted in a solution buffer of 90% PBS, 5% PEG 
400, 5% Tween 80. 5 month-old wt and PA mice were injected intraperitoneally (i.p.) 
every day for a week with 2 mg/kg of rapamycin. After seven days of treatment, mice 
were sacrificed by CO2 inhalation and hearts were excised, snap-frozen in liquid 
nitrogen and stored at -70°C until use. 
Human samples. Human plasma samples were used for miRNA analysis. PA patients’ 
plasma were remnants of samples referred to the laboratory for follow-up with the 
appropriate informed consent. Nine were from PCCB deficient patients and one from a 
PCCA deficient patient (Table 1). All the samples were taken during periods of 
metabolic stability of the patients and time after being diagnosed with DCM or Long Qt, 
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except for P5, who was diagnosed with emerging DCM at the time of plasma sampling. 
Matched control plasma samples were obtained from Sera Lab Ldt. 
(http://www.seralab.co.uk/), collected from consented anonymous donors. The Ethical 
Committee (Universidad Autónoma de Madrid) approved this study. All human 
experimental methods were performed in accordance with the relevant guidelines and 
regulations. 
Cell culture and propionate treatment. HL-1 cardiomyocytes were cultured in 
Claycomb medium (Sigma, Saint Louis, Missouri, USA), supplemented with 10% fetal 
bovine serum, glutamine 20 mM and a cocktail of antibiotics. To ensure proper growth 
of the cells, 0.3 M ascorbic acid (Sigma, Saint Louis, Missouri, USA), 1 mM retinoic 
acid (Sigma, Saint Louis, Missouri, USA) and 5 mg/mL insulin (Sigma, Saint Louis, 
Missouri, USA) were added to the medium. Before cell seeding, plates were treated for 
24 hours with 0.1% gelatin and 25 μg of fibronectin (Sigma, Saint Louis, Missouri, 
USA). Three days before propionate treatment, cells were seeded in P6 plates (~200,000 
cells per well). Then, 5 mM of sodium propionate (Sigma, Saint Louis, Missouri, USA) 
was added to the medium and refreshed at 48 hours. Cells were collected for mRNA 
and miRNA analysis and reactive oxygen species (ROS, H2O2) quantification four or 
eight days after initiation of treatment. To determine ROS production by flow 
cytometry, cells were detached by trypsinization and cellular fluorescence intensity was 
measured after 30 minutes incubation at 37 °C with the H2DCFDA probe in the FACS 
Canto II (Becton Dickinson Biosciences). Data analysis was performed using FlowJo 
program. 
RNA and protein extraction. For RNA extraction, both tissue and cell (HL-1 
cardiomyocytes) samples were treated for 20 minutes with lysis buffer (supplied by 
Qiagen) and proteinase K. Then, total RNA was extracted using miRNeasy mini kit 
(QIAGEN, Hilden, Germany) according to manufacturer’s instructions. Concentration 
and integrity of total RNA was measured in the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies Inc, Rockland, DE, USA). RNA isolation from human plasma 
samples was performed using miRNeasy Serum/Plasma Advanced Kit (QIAGEN, 
Hilden, Germany), following the manufacturer´s instructions. 200 μL of plasma were 
used and RNA was eluted in 20 μL.  
Protein samples were obtained from HL-1 cells and from frozen mouse heart tissue. 
HL-1 cells were harvested by trypsinization and treated with lysis buffer (10 mM Tris-
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HCl 7.5, 150 mM NaCl, 0.1% Triton and 10% glycerol), protease and phosphatase 
inhibitors. Samples were subjected to freeze-thawing cycles and proteins were collected 
in the supernatant fraction after centrifugation of the cell lysates. Mouse heart tissue was 
pulverized using screws cooled in liquid N2 and proteins were isolated by disrupting the 
powdered tissue in lysis buffer (50 mM Tris-HCl  pH 7.5, 150 mM NaCl, 0.1% Triton 
X-100, 1 mM EDTA and 10% glycerol) using TissueLyser (two rounds of 90 seconds at 
20 Hz) followed by centrifugation at 10,000 g for 30 minutes at 4ºC. Protein 
concentration in the supernatant was measured using the Bradford method (Bio-Rad 
Laboratories). 
miRNA analysis. 5 ng of total RNA obtained from heart tissue or HL-1 cells and 4 μL 
of the RNA eluate from plasma samples were used for retro-transcription using the 
miRCURY LNA RT Kit (QIAGEN, Hilden, Germany). miRNAs were amplified using 
specific LNA primers and miRCURY LNA SYBR Green PCR kit (QIAGEN, Hilden, 
Germany), in a LightCycler 480 instrument (Roche Applied Biosciences, In, USA), 
according to the manufacturer’s instructions. For tissue and cellular samples, miR-423-
3p and snRNA U6 were used as endogenous controls; for plasma samples, miR-103a-3p 
was used for normalization. Relative miRNA expression was quantified using the 
comparative threshold method after the detection of the different Ct values for the 
reference miRNA and the target ones, using the 2-ΔΔCt method. All samples were run in 
triplicate.  
mRNA quantification. For gene expression analysis, cDNA was obtained by 
retrotranscription of 500 ng of total RNA from mouse heart samples or HL-1 cells using 
NZY First-Strand cDNA synthesis kit (NZYTech, Lda, Lisbon, Portugal). Nppa (ANP), 
Nppb (BNP), Myh7 (β-MHC), Col1a1 (COL1A1), Col1a2 (COL1A2), Col3a1 
(COL3A1) and Med13 (THRAP1) genes were amplified with specific primers 
(available upon request) using Perfecta SYBR Green FastMix kit (Quanta Biosciences, 
Beverly, MA, USA) in a LightCycler480 II instrument (Roche Applied Biosciences, In, 
USA). Gapdh was used as endogenous control and quantification was done using the 2-
ΔΔCt method. 
Phosphatidylinositol 3 kinase-protein kinase B (PI3K/AKT) signaling pathway 
expression profiling. Total RNA (100 ng/µL) from wt and PA mouse heart tissue was 
reversed transcribed using NZY First-Strand cDNA synthesis kit (NZYTech, Lda, 
Lisbon, Portugal). cDNA samples were pooled in four control and four PA groups. 
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mRNA profiling was performed with Mouse PI3K-AKT Signaling Pathway RT² 
Profiler PCR Array (QIAGEN, Hilden, Germany), which contains mouse specific 
primers for 84 genes involved in the PI3K-AKT pathway. Real-time PCR amplification 
was performed with Perfecta SYBR Green FastMix (Quanta Biosciences, Beverly, MA, 
USA) in an ABI 7900HT instrument (Applied Biosystems, CA, USA). The ABI 
software was used to obtain raw threshold cycle (Ct) value for each mRNA. qRT-PCR 
reactions and analysis were carried out at Genomics Core Facility, Parque Científico de 
Madrid, Spain. Relative quantification or fold change for each mRNA was calculating 
with the 2-ΔΔCt method, using 5 housekeeping genes (Gapdh, B2m, Actb, Ywhah and 
Gusb) as internal controls.  
Western blotting. For western blot analysis, equal amounts of protein (50-75 µg) were 
loaded into 10% or 12% SDS-polyacrylamide gels. Proteins were transferred into a 
nitrocellulose membrane using the iBlot® Dry Blotting System. For the analysis of total 
and phosphorylated proteins, membranes were blocked for 1 hour with 5% non-fat milk 
or 3% BSA respectively, in 0.1% TBS-tween and incubated overnight with the 
corresponding primary antibody: LC3B (1:500, Cell Signaling Technology, Danvers, 
MA, USA), caspase 3, caspase 9, LAMP1, Phospho-p70 S6 Kinase (Thr389), p70 S6 
Kinase, S6 Ribosomal Protein, Phospho-4E-BP1 (Ser65), Phospho-S6 Ribosomal 
Protein (Ser240/244), 4E-BP1 (all of them used at 1:1,000, Cell Signaling Technology, 
Danvers, MA, USA) and p62/SQSTM1 (2C11) (1:5,000, Abnova-novus biologicals, 
USA). Secondary antibodies were goat anti-rabbit and goat anti mouse (1:5,000 or 
1:10,000 respectively, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Antibody 
against GAPDH was used as loading control (1:5,000, Abcam, Cambridge, UK). 
Enhanced chemiluminescence reagent (ECL, GE Healthcare) was used for protein 
detection. Band intensity for each protein was quantified with BioRad GS-900 
Densitometer (BioRad) and ImageLab program.  
Bioinformatics tools. miRNA function, their targets and their expression profile were 
analyzed using miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/), 
TargetScan database (http://www.targetscan.org/vert_72/) and Human miRNA Tissue 
Atlas (https://ccb-web.cs.uni-saarland.de/tissueatlas/). 
Statistical analysis. Data were presented as mean ± SD. To analyze significant 
differences, the distribution of two groups was compared using two-tailed unpaired T-
test distribution; three or more groups were compared using ANOVA method followed 
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by the Tukey's honestly significant difference (HSD) or Games Howell post hoc test. P 
values below 0.05 were considered statistically significant: *p<0.05; **p<0.01; 
***p<0.001. 
Results 
Echocardiographic and biochemical studies  
In order to characterize the cardiac phenotype of the hypomorphic PA mouse 
model, we performed echocardiographic studies in wt and Pcca-/-(A138T) male mice 
(n=6 wt group and n=7 PA group) at 5 and 8 months of age. Longitudinal 
echocardiographic analyses revealed cardiac alterations characterized by signs 
suggestive of diastolic dysfunction (Table 2). The diastolic interventricular septal 
thickness (IVS; d) was increased in PA mice compared with that of control mice. 
Diastolic left ventricular posterior wall thickness (LVPW; d) was also significantly 
increased in hypomorphic 5 month-old mice compared with wt mice. No differences 
were found in the analysis of the left ventricular mass (LV mass). E/A ratio, a clinical 
marker of diastolic dysfunction, was slightly increased in PA mice at 5 (35% increase) 
and 8 (20% increase) months of age as compared to wt (Table 2) not reaching statistical 
significance. In addition, PA mice had an elevation in left ventricle internal diameter 
(LVID) at end-diastole at both ages, indicating LV chamber dilation and DCM. We 
observed a reduction in the ejection fraction (EF) and fractional shortening (FS) 
parameters in 8 month-old PA mice compared to wt although not reaching statistical 
significance (Table 2). Heart rates were similar between wt  and PA mice. 
Further to functional abnormalities, PA mice also displayed elevated gene 
expression of the fibrosis markers Col1a1 and Col3a1 at 5 months of age 
(Supplementary Fig 1). The expression of Nppa, Nppb and Myh7, coding for cardiac 
damage markers ANP, BNP and β-MHC, is elevated at this time point [6, 10], with no 
statistically significant changes detected at earlier (2 months) or later (10 months) ages 
(data not shown).  
Histology and electron microscopy studies 
Mitochondrial dysfunction inherent to PA can lead to lipid accumulation in 
tissue; lipid droplets have been observed in muscle tissue from PA patients [14]. 
Cardiac tissues from the mice were analyzed by TEM.  Hearts from wt mice contained 
regular sarcomere banding patterns with mitochondria evenly dispersed in relatively 
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straight bands with no lipid droplets (Fig 1, top row).  In contrast, there were increased 
numbers of light grey and white circular bodies consistent with the presence of lipid 
droplets in the hearts from PA mice (Fig 1, bottom rows).   
Expression levels of cardiomiRs in PA mice hearts 
We selected a series of 13 miRNAs expressed in cardiac tissue and reported in 
the literature to be associated with cardiomyopathies (Supplementary Table 1) for their 
analysis in heart samples from wt and PA mice (n=5 per group, 5 month-old males and 
females). The results showed a significant upregulation of 11 miRNAs, with miR-208a, 
miR-22, miR-199a and miR-199b exhibiting the highest fold-increase (13-fold to 15-
fold) compared to samples from wt mice (Fig 2). The expression of miR-208a in PA 
mice hearts was further examined at different ages, in 2 month-old mice there is a 
moderate increase (3-fold compared to wt mice) while in 10 month-old mice its 
expression is reduced (0.2-fold) (data not shown).  
Analysis of signaling pathways and selected miRNA targets 
Our next aim was the investigation of altered cellular processes regulated by the 
identified miRNAs that could underlie the development of cardiomyopathy in PA. Thus, 
we analyzed signaling pathways and selected target genes of the miRNAs, previously 
functionally validated by modulating miRNA levels in different cellular and/or animal 
models of heart disease (Supplementary Table 1). 
As a first step, we performed gene expression profiling in PA and wt mice heart 
samples (n=8, grouped in two pools of 4 mice each, 5 month-old males and females), 
analyzing 84 genes involved in the PI3K/AKT pathway that has been shown to play a 
role in cardiac remodelling [15] and is regulated by several of the identified cardiomiRs. 
The analysis included members of the AKT and PI3K families and their regulators, 
genes involved in regulation of actin organization and cell migration, glycogen synthase 
kinase 3 (GSK3) inactivation and β-catenin accumulation, and genes in the insulin-like 
growth factor 1 (IGF-1), mammalian target of rapamycin (mTOR), autophagy and 
apoptotic pathways. 18 genes were downregulated and 15 upregulated, considering fold 
changes of >1.3 or <0.7 (Fig 3). Among the upregulated genes there are several that 
promote cell survival/proliferation and/or with pro-hypertrophic function such as Jun, 
Igf1r, Eif4b, Raf1, Pak1, Mtor, PIk3ca, Tcl1 or Fos. Genes involved in inflammatory 
responses were also found up-regulated (Tlr4, Tirap, Myd88). On the other hand, genes 
regulating apoptosis (Csnk2a1, Fasl, Foxo3) exhibited decreased expression, as well as 
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others regulating NFκΒ activation (Chuk, Irak1, Nfkbia). Gja1, encoding gap junction 
protein alpha expressed in the heart left ventricle and important for contraction, was also 
found downregulated, as well as Pten and Tsc2, known inhibitors of the mTOR 
pathway. The observed downregulation of Pten, validated target of miR-22, correlates 
with the observed increased expression of this miRNA, which is essential for cardiac 
growth and remodelling in response to stress [16]. Other targets of the identified 
dysregulated miRNAs in PA mice hearts are indicated in Fig 3. 
In a next step, we sought to analyze in depth cardiac autophagy and mTOR 
activation in PA mouse heart tissue, based on the results of the PI3K/AKT array and on 
the described involvement of the mTOR pathway in the regulation of cardiomyocyte 
cell size mediated by miR-199a [17], one of the miRNAs which we found most highly 
upregulated. The results showed a significant decrease in the autophagic marker 
LAMP1 and an increase in p62, indicating autophagy impairment (Fig 4A) as well as 
activation of components of the mTOR signaling pathways in PA mice heart compared 
to controls (Fig 4B). Activation signature of the mTOR pathway and autophagy 
decrease were validated using the commercially available drug rapamycin. Acute 
treatment with this mTOR inhibitor (seven consecutive daily i.p. injections with 2 
mg/kg of rapamycin in wt and PA mice, n=9-10 per group) effectively reverted some of 
these alterations, increasing autophagy process (increasing levels of LAMP1 and 
decreasing levels of p62) (Fig 4C) and decreasing levels of proteins involved in mTOR 
pathway (Fig 4D). Notably, rapamycin treatment in PA mice decreased the expression 
of Nppb and Myh7 (Supplementary Fig 2). 
In addition, we also investigated specific previously functionally validated 
targets of the dysregulated miRNAs, which could be contributing to PA cardiac 
dysfunction. miR-199a has been described to regulate metabolic switching from fatty 
acid oxidation to glycolysis during heart remodelling, through repression of the 
expression of cardiac peroxisome proliferator-activated receptor δ (PPARδ) [18]. miR-
208a is involved in the control of cardiac contractility in response to stress or 
hypothyroidism through the inhibition of MED13, a cofactor of the thyroid hormone 
nuclear receptor that represses β-MHC expression in the adult heart [19]. miR-133a 
represses the expression of caspase 3 and caspase 9 protecting cardiomyocytes from 
oxidative stress-mediated cell death [15]. Caspase 3 has also been validated as a direct 
target of miR-378. Accordingly, in PA mice heart, we could confirm a significant 
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decrease in the expression of these targets (Ppard, Med13, Casp3 and Casp9) 
(Supplementary Fig 3).  
Effect of propionate in HL-1 cardiomyocytes 
To investigate potential mechanisms triggering miRNA dysregulation in PA 
mice hearts and the contribution of accumulating toxic metabolites to the development 
of cardiac dysfunction, we analyzed the effect of propionate treatment in the cardiac 
murine cell line HL-1. Cells were treated during 4 days with 5 mM propionate 
(concentration detected in patients’ plasma [20]) and the 4 miRNAs showing highest 
upregulation in PA mice hearts (miR-208a, miR-199b, miR-22 and miR-199a) were 
analyzed, as well as cardiac dysfunction markers and ROS levels. Propionate treatment 
resulted in an increase in ROS levels, as previously reported in different in vitro and in 
vivo models [7] and induced the expression of Nppb and Myh7 (Fig 5A and 5B). 
miRNA levels did not vary significantly after 4 days but longer exposures to propionate 
(8 days) resulted in the upregulation of miR-22, miR-199a and miR-199b, while miR-
208a levels decreased (Fig 5C).  
miRNA analysis in PA patients’ plasma samples 
Up to 70% of PA patients develop cardiomyopathy [8, 9]. In order to determine 
the translatability of the results obtained in the mouse model we investigated the 
presence and the expression levels of the identified cardiomiRs in PA patients’ plasma 
samples compared to matched control samples (>12 years of age; n=10) (Table 1). In 
this preliminary study we analyzed 5 miRNAs showing highest upregulation in PA mice 
hearts (miR-208a, miR-22, miR-199a, miR-199b and miR-29a) as well as miR-133a, a 
circulating miRNA studied in relation to fibrosis and DCM [21]. miR-208a and miR-
199b could not be detected, which in the case of miR-208a could be attributed to the 
specific amplification technique used [22]. miR-22, mir-29a, miR-133a and miR-199a 
were decreased in PA patients’ samples (Fig 6A). Closer inspection of the miRNA 
profile in individual patient samples revealed a specific pattern shared by most of them 
(Fig 6B), even though not all patients exhibited the same cardiac phenotype (Table 1). 
Only patient 2 showed a clearly different miRNA profile with highly increased levels of 




Cardiomyopathy is a major health problem in PA patients, strongly influencing 
overall morbidity and mortality [8, 9]. Although PA usually presents neonatally and is 
today included in newborn screening programs in some countries, there are cases of 
milder, even asymptomatic, patients presenting later with cardiomyopathy. To date, it is 
largely accepted that the bioenergetic deficiency and oxidative stress due to a secondary 
mitochondrial dysfunction contributes to the progressive decline of myocardial function 
in PA. We have recently shown redox-mediated alterations in sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA2a) function impairing Ca2+ handling as a new 
pathological mechanism involved in PA cardiomyopathy [11], although additional 
factors are probably involved. There is an unmet clinical need to advance further in the 
understanding of PA cardiac pathology, to develop novel, better suited treatments and to 
identify biomarkers for earlier diagnosis of this complication and for response to 
treatment. miRNAs are known to play an important role in cardiac development, 
dysfunction and failure. In this study we used the hypomorphic Pcca-/-(A138T) PA 
mouse model to analyze the expression of cardiac enriched miRNAs and their targets 
governing biological processes linked to cardiovascular disease.  
Our results show structural defects and signs of diastolic dysfunction in PA 
mouse hearts and confirm the presence of specific markers of cardiac damage, including 
i) gene expression reprogramming, as shown by upregulation of early immediate genes 
(c-Fos, Jun) and reactivation of a set of fetal cardiac genes (Nppb and Myh7), ii) 
increase in the expression of collagen genes indicating the appearance of myocardial 
fibrosis, and iii) increase in protein synthesis and decrease in autophagy (mTOR 
activation).  In addition, we observe a decrease in caspases 3 and 9 levels, indicative of 
cardiac remodeling that accompanies the progression of cardiac pathology. We could 
also confirm a significant decrease in the expression of Ppard, coding for PPARδ, the 
critical regulator of energy metabolism in heart, which is shifted towards glycolysis in 
the failing heart. In line with this, we previously documented a significant reduction in 
the fatty acid oxidation enzyme HADHA in PA mouse hearts [23]. In brief, the data 
reflect the complex cellular phenotype with multiple signaling pathways altered in PA 
mouse hearts. 
Notably, this is the first study describing the in vivo dysregulation of cardiac-
enriched miRNAs in PA which could be involved in the development of cardiac 
alterations. We sought for potential causes and consequences of those changes and 
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identified propionate as an exogenous factor which may trigger the alterations in the 
expression of these miRNAs, although other mechanisms may act in concert. miRNA 
expression is regulated at both transcriptional and post-transcriptional levels, with 
documented direct and indirect effects of certain endogenous (chemokines, hormones) 
and exogenous (xenobiotics) compounds [24]. Propionate is a known histone 
deacetylase inhibitor [25] and cardiac remodelling and hypertrophy has been linked to 
histone acetylation [26]. In addition, propionyl-CoA was recently shown to stimulate 
transcription through an increase in histone 3 lysine propionylation (H3K4pr), thereby 
linking the metabolic state of the cell with chromatin architecture [27]. Livers of the 
hypomorphic PA mouse model display higher levels of H3K14pr which revert to wild-
type levels after gene therapy [27]. Another plausible explanation is that miRNA 
dysregulation may be driven by a ROS signaling mechanism, as increased propionate 
levels induce ROS elevation resulting in oxidative damage, both in vivo and in vitro as 
shown in this work and in previous studies [28]. In turn, ROS are known to activate 
signaling kinases and transcription factors, mediate apoptosis and stimulate cardiac 
fibroblast proliferation leading to cardiac remodelling [29].  
Eleven of the studied miRNAs were found upregulated in the PA mouse heart, 
with miR-208a, miR-199b, miR-22, miR-199a and showing >13-fold increased levels 
compared to wt samples. Except for miR-208a, the expression of these miRNAs was 
induced in cardiomyocytes upon propionate treatment.  miR-208a plays a crucial role in 
heart health and disease, regulating cardiac contractility, hypertrophy pathway 
components and cardiac conduction system. It is encoded by an intron of the Myh6 gene 
and upon cardiac stress induces the expression of the dominant embryonic myosin 
isoform β-MHC (which we find increased in PA mouse hearts), contributing to 
diminishing cardiac performance [19]. In DCM patients this miRNA has been described 
as a predictor of cardiac death and progression of heart failure, with higher 
endomyocardial levels associated with adverse clinical outcomes [30]. Recently, a 
negative feedback loop between ROS and miR-208a was recently shown in cultured rat 
cardiomyocytes, with ROS attenuating miR-208a expression [31], which could explain 
our results in propionate treated cardiomyocytes. 
miR-199a is involved in mTOR activation and autophagy and in mitochondrial 
fatty-acid oxidation impairment [17, 18]. We have confirmed decreased Ppard 
expression, a direct target of miR-199a mediating cardiac fuel switch from fatty acid to 
16 
 
glucose, which is also observed in normal rat hearts perfused with high exogenous 
propionate [32], again providing a possible link between the accumulating metabolite in 
PA, a dysregulated miRNA and developing heart failure. Our data have also revealed an 
impairment in the autophagic flux in PA mouse hearts due to elevated mTOR signaling, 
which could contribute to cardiac pathology and that could be restored by rapamycin. 
Rapamycin ester temsirolimus, an FDA-approved drug with more favorable 
pharmaceutical properties and mild side effects [33], may be an attractive therapeutic 
option for PA patients exhibiting cardiomyopathy. 
Furthermore, the miRNAs identified in our study can be considered per se as 
potential therapeutic targets. miRNA-based therapeutics is currently an increasing field 
of research, with the development of drugs aiming to inhibit (antagomiRs) or 
overexpress (miRNA mimics) specific miRNAs altered in disease [34]. Future studies 
will elucidate whether this approach is applicable in the PA mouse model, due to the 
observed complex changes in different cellular processes regulated by multiple 
miRNAs. In DCM, few miRNAs have been directly implicated as therapeutic targets, 
although the overexpression of miR-699a resulting in a long-term benefit for severe 
chronic myotonic dystrophy-associated DCM represents a landmark case [35]. 
The presence of dysregulated circulating cardiomiRs in PA patients’ samples 
provides strong evidence of the clinical significance of our study. As in other diseases  
[36] we observe opposed changes in expression in tissues versus plasma samples 
(upregulated and downregulated, respectively), which can be due to different regulatory 
processes in mice and humans,  as well as to the fact that miRNAs are mostly actively 
secreted as a specific biological process and circulating miRNAs do not reflect 
intracellular levels. Although the low number of samples analyzed (a common 
limitation in the field of rare genetic diseases) precludes drawing definitive conclusions, 
the distinct miRNA signatures also support their potential applicability as biomarkers of 
disease progression or of response to treatment. However, given the low concentration 
of circulating cardiomiRs in plasma samples, which is further decreased in PA patients, 
the use of alternative profiling methods such as next generation sequencing which may 
provide lower detection limits and accurate quantification [37], should be evaluated and 
differences rigorously validated.  It is worth noting that some of the patients showing an 
altered circulating miRNA profile exhibited no cardiac manifestations at the time of the 
analysis and that the only patient under specific treatment for cardiac disease exhibits a 
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different miRNA profile (P2 in Fig 6B). Our results constitute a starting point for a 
wider international study including different PA patient cohorts with documented 
clinical histories relative to cardiac phenotypes. It will be interesting to confirm if early 
metabolic and signaling dysregulations and miRNA and gene expression alterations 
precede overt cardiomyopathy in PA, as has been documented for other monogenic 
diseases [38]. In addition and as cardiomyopathies may be reversed after liver 
transplantation in PA patients [39], the analysis of circulating cardiomiRs before and 
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LEGENDS TO FIGURES 
 
Figure 1. Transmission electron microscopy of cardiac tissue.  Heart tissue of wt and 
PA mice was analyzed by TEM. Panels on the left were viewed at 5,000X 
magnification, with bars representing 5 μm. Panels on the right correspond to the image 
within the boxes shown at 20,000X magnification, with bars representing 1 μm. 
Figure 2. Relative expression analysis of selected miRNAs specifically expressed in 
cardiac tissue (cardiomiRs). miRNA expression analysis was performed by qRT-PCR 
in heart samples from wt and PA mice (5 month-old, n=5 per group). Statistical 
significance was determined by Student´s t-test. *p<0.05; **p<0.01, ***p<0.001. RQ: 
relative quantity. 
Figure 3. Dysregulated genes in PA mice hearts identified in the expression array 
of PI3K/Akt signaling pathway. Gene expression analysis was performed by qRT-
PCR from cardiac pooled samples of wt and PA mice (5 month-old, n=8 per group). 
Upregulated miRNAs identified in PA mice hearts are shown above their respective 
targets. 
Figure 4. Analysis of protein levels of autophagy and the mTOR related signaling 
pathways. Heart samples from 5 month-old wt and PA mice (n=5-10 per group) were 
analyzed by Western blot. Representative blots are shown on the left and on the right 
the corresponding quantification by laser densitometry of proteins involved in 
autophagy (LC3BI, LC3BII, LAMP1 and p62) (A, C) and protein synthesis (S6K, S6, 
4EBP1, and the phosphorylated forms) (B, D). In each blot, GAPDH was used as a 
loading control. In C and D, protein values are shown relative to untreated controls. 
Statistical significance was determined by Student´s t-test. *p<0.05; **p<0.01, 
***p<0.001. 
Figure 5. Effect of propionate in the cardiac murine cell line HL-1. Cells were 
treated with 5mM propionate for 4 days and (A) ROS production was quantified by 
flow cytometry using the H2DCFDA probe,  (B) expression of cardiac damage markers 
Nppb and Myh7 were analyzed by qRT-PCR. (C) cardiomiRs (miR-22, miR-199a/b and 
miR-208a) were analyzed by qRT-PCR after 4 and 8 days of propionate treatment. 
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Statistical significance was determined by Student´s t-test. **p<0.01, ***p<0.001. RQ: 
relative quantity. 
Figure 6. Relative levels of miR-22, miR-29a, miR-133a and miR-199a in plasma 
samples from PA patients. miRNA relative expression analysis was performed by 
qRT-PCR. All samples were from PA patients and controls older than 12 years (n=10 
per group). (A) Representation of the mean levels of cardiomiRs and (B) miRNA 
profile for each patient. Statistical significance was determined by Student´s t-test. 
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Legends to Supplementary Figures 
 
Supplementary Figure 1. Relative mRNA levels of fibrotic markers Col1a1, Col1a2 
and Col3a1. Gene expression analysis was performed by qRT-PCR in heart samples 
from wt and PA mice (5 month-old, n=5 per group). Statistical significance was 
determined by Student´s t-test. *p<0.05. 
Supplementary Figure 2. Expression of cardiac damage markers in heart of wt and 
PA mice after rapamycin treatment. Expression levels of Nppb and Myh7 (coding for 
BNP and β-MHC, respectively) were analyzed by qRT-PCR in 5 month-old wt and PA 
mice (n=9-10 per group). Statistical significance was measured by ANOVA followed 
by the Tukey's honestly significant difference (HSD) or Games Howell post hoc test. 
*p<0.05; **p<0.01. NT: non treated; RAPA: rapamycin treated. 
Supplementary Figure 3. Expression analysis of targets of upregulated 
cardiomiRs. Analysis of mRNA levels of (A) Ppard (miR-199a target) and (B) Med13 
(miR-208a target) was performed by qRT-PCR in wt and PA mice hearts (5 month-old, 
n=5 per group). (C) Analysis of protein levels of Caspase 3 and Caspase 9 was carried 
out by western blot using GAPDH as loading control in wt and PA mice (5 month-old, 
n=8 per group) and protein quantification was performed by laser densitometry. 
Statistical significance was determined by Student´s t-test. *p<0.05; **p<0.01, 
***p<0.001. 
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